Evergreen Select: Jim Miller on Big Pharma execution, 3D scaffolding, and the Hybrid Meat strategy
Investment Climate · Alex Shandrovsky
Audio is streamed directly from the publisher (api.riverside.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Episode 82: Evergreen Select: Jim Miller on Big Pharma execution, 3D scaffolding, and the Hybrid Meat strategy
In this episode, I sit down with Jim Miller, President and CEO of Evergreen Select, a cultivated meat company that has raised roughly $55M to date, backed heavily by lead investor S2G. Jim brings over 30 years of Fortune 500 biotech and Big Pharma execution (including COVID vaccine commercialization) to the cultivated meat sector. He breaks down why Evergreen abandoned complex plant-based hybrid blends in favor of a direct "drop-in" strategy: blending their 100% lean, non-GMO cultivated beef biomass directly with traditional ground beef. We dive into the science behind their 3D bovine scaffolding that allows them to harvest solid chunks instead of a liquid slurry—achieving massive titers north of 350 grams per liter—and how they are positioning their product as a hedge against the volatile spot prices of the traditional beef industry.
🎧 Listen to the full episode to hear Jim’s masterclass on extreme board transparency and why daily scrums are vital for startup survival.
Key Facts Evergreen Select:
- Goal: To supply meat processors with a highly scalable, non-GMO cultivated lean beef biomass that blends seamlessly with traditional ground beef to stabilize costs and supply.
- Milestone: Successfully raised ~$55M to date (with a recent $8M injection) while advancing regulatory dossiers for commercialization in both the US and Singapore.